Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Amyloid-β (Aβ) and tau come in a variety of forms and assembly states, not all of which are toxic. In this Review, Polanco and colleagues explain the clinical and therapeutic implications of this new understanding while highlighting the physiological and pathogenetic roles of Aβ and tau.
To coincide with the 200th anniversary of the publication of An Essay on the Shaking Palsy by James Parkinson, Goedert and Compston explore the origins of the eponym 'Parkinson's disease'. Although Jean-Martin Charcot is often credited with introducing the name in the 1880s, it can actually be traced back to an 1865 publication by William Rutherford Sanders.
Parkinson disease (PD) affects up to 10 million people worldwide and is clinically diagnosed. Molecular phenotyping of patient samples might help to corroborate diagnosis, and a new study suggests that blood-based gene expression profiling might distinguish between patients with PD and those without. However, experience suggests that additional replication is needed.
Cognitive ageing is a complex public health, social and economic problem that demands a bold response — a paradigm shift that leads science and society to view brain health across the lifespan of every individual as critically important. Implementation of 'Life's Simple 7' is a laudable step in that direction.
Two decades after antisense oligonucleotides (ASOs) were initially identified as agents capable of modulating RNA processing and protein expression, the first antisense oligonucleotide (ASO) therapies have now been approved for the treatment of neurological disease. Here, Rinaldi and Wood discuss our current understanding of ASO pharmacology, and the future prospects for ASO-mediated treatment of neurological disease
Idiopathic rapid eye movement (REM) sleep behavioural disorder (RBD) is now recognized as an early marker of α-synucleinopathies. Here, Högl and colleagues review potential biomarkers for RBD and summarize the evidence for a prodromal stage, which might enable disease-modifying intervention. In light of these advances, they reconceptualize idiopathic RBD as isolated RBD.
A compelling need exists for a more reliable risk evaluation of natalizumab- associated progressive multifocal leukoencephalopathy (PML). A new report proposes a refined protocol that uses updated patient-based data and cumulative risk evaluation to provide an improved assessment of the annual risk of PML for patients positive for JC virus.
Inadequate remyelination is central to degeneration and disability in patients with multiple sclerosis (MS); however, all currently approved therapies for MS are primarily immunomodulatory. Here, Martin Stangel and colleagues review our current knowledge of remyelination in MS, discuss results from clinical trials of remyelination-enhancing therapies, and evaluate the opportunities for future regenerative treatments.
The causes of migraine remain unknown despite the high prevalence and societal burden of this disorder. Here, the authors highlight how advances in imaging and genetic studies of migraine provide insights into the underlying mechanisms of this disorder; furthermore, they discuss the potential for genetic and imaging biomarkers to improve our ability to prevent and treat migraine attacks.